Randomized Controlled Trial of Sertraline, Prolonged Exposure Therapy and Their Combination in OEF/OIF with PTSD
Abstract
The current proposal aims to directly compare the psychotherapy and medication treatments for PTSD considered to have the most evidence for effectiveness. While both SSRI and PE have demonstrated efficacy, there are significant individual differences in clinical responses to both treatments. To achieve best clinical outcomes and to utilize available treatment most effectively, it is critical to examine how PTSD and related psychopathology and functional impairment change with these treatments alone and in combination. Further, in order to inform clinical practice, we plan to examine psychological and neurobiological predictors of response to treatment and mechanisms of change during treatment (pre to post treatment change) based on previously identified predictors, including emotion regulation and processing with fMRI in response to emotional challenge tasks, DNA and mRNA (pre and post treatment), and cortisol response to awakening. The primary activity and focus this year has been on recruitment and retention. We obtained funding to expand to 2 new CBOCs that are under the coverage of current IRBs. We were also approved for a 1-year no cost extension. Completion of study research and treatment protocol is our primary focus for the coming year. As of 12/21/15, we have recruited and randomized 203 Veterans and 92 Veterans have completed the Week 52 final study assessment visit.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2015
- Accession Number
- AD1002983
Entities
People
- A. M. Rogers
- Anthony P King
- Benjamin Kovachy
- Brian Martis
- Carolyn Allard
- Hugh Myrick
- Israel Liberzon
- Katherine Porter
- Linette Dubois
- Luan Phan
- Margaret R. Venners
- Mark Hamner
- Mark West
- Michelle Pompei
- Murray B. Stein
- Naomi Simon
- Peter W Tuerk
- Ron Acierno
- Sheila A. Rauch
- Sonya B Norman